Subscribe now GoodRx respects your privacy and we do not sell your personal information. Due to this risk, it is recommended to avoid the medication in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious abnormal heart rhythms or other serious cardiac problems. Phentermine should not be used in people with severe high blood pressure, glaucoma, or a history of drug abuse. Long-term use has the potential to cause psychological dependence. Phentermine belongs to the group of medicines known as appetite suppressants. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. There are not long-term studies done on phentermine since it is only indicated for short-term use according to prescribing information. Arley Ryder talks about Phentermine, illegal pharmacies and dangers of buying Phentermine online
Some of those side effects include: A very popular drug for weight-loss in the early s was called Phen-fen. Phen-fen was a combination of Phentermine and Fenfluramine. As time went on, more and more side effects were reported with Phen-fen. In response to this, Fenfluramine was taken off the market. Some time later several of the brand name manufacturers discontinued their brand of Phentermine as well.
Fastin was one of them. Fastin was discontinued in In this case, there is no difference between prescription Fastin and generic Phentermine other than the generic form is generally cheaper and that is why many people buy generics especially when they are the same thing as the branded product. Interestingly, Hi-Tech Pharmaceuticals, the manufacturer of Fastin OTC, was able to purchase the Fastin name and trademark from the former prescription manufacturer which happens to be Beecham.
So, Hi-Tech began producing a line of dietary supplements. So far they have 3 Fastin products for over-the-counter. These dietary supplement contain alkaloids which may have similar side effects as the prescription Fastin which includes: It is important for over-the-counter OTC medications as well as prescription drugs to undergo clinical trials to determine safety ad efficacy. The results in these subjects were then compared with the findings in randomly selected cardiac patients with heart disease that was not caused by Fen—Phen.
The number of people with aortic regurgitation fell with time after the withdrawal of Fen—Phen. However, among those who continued to have aortic regurgitation, there was an increase in the number of those who progressed from mild to moderate regurgitation, with an associated increase in left ventricular end-diastolic and end-systolic dimensions and left ventricular ejection fraction.
The incidence of tricuspid and mitral regurgitation fell with time, while pulmonic and aortic regurgitation tended to increase or become more severe when present. Dilatation of the pulmonary ring, resulting from raised pulmonic pressures, with subsequent pulmonary regurgitation and reduced pulmonary artery pressures, appears to be a functional change in the hearts of these individuals with unknown long-term consequences. Adult and Pediatric Seventh Edition , The dose combinations are: Both phentermine and topiramate alone cause weight loss and are available as generics, although the specific mechanism of either is not known.
Similarly, the weight-loss mechanism of the combination is not known but is attributed to a reduction in appetite. In clinical studies, phentermine -topiramate reduced body weight by 8. Phentermine -topiramate carries risks of several serious side effects. Notably, topiramate is a recognized teratogen, at least at the higher doses used for the treatment of epilepsy. The combination of phentermine -topiramate carries a warning of birth defects cleft lip and palate in the offspring of pregnant women taking the combination therapy.
Pregnant women should not take the drug, nor should women who are trying to conceive or are at risk for becoming pregnant. The combination is only available through restricted pharmacies as Qsymia. Several drugs approved for treatment of diabetes also cause weight loss; these include metformin, pramlintide, and the GLP-1 agonists, exenatide and liraglutide. Bupropion, approved for the treatment of depression, may be useful in treating obesity. A combination of bupropion and naltrexone is currently under consideration for approval pending additional safety studies.
Targets of investigational therapies include the melanocortin 4 receptor and others. There is sufficient turnover in these clinical development programs that any list is almost immediately out of date and incomplete. Readers should refer to a recent review for a more complete discussion of current developmental candidates. The biggest limitation of lifestyle interventions is the tachyphylaxis; most patients return to their initial weight within 5 years.
It remains to be determined if pharmacotherapy can be used to assist with weight maintenance after weight reduction. Bello 1 , in Side Effects of Drugs Annual , A year-old woman taking phentermine She typically took phentermine intermittently, two to three times a week. However, for the last 2 weeks she increased the medication to two to three times daily. She had a pack-year history of smoking tobacco.
Upon arrival her vital signs were within the normal range but CT scans reveal a subarachnoid hemorrhage SAH in the basal cistern. Patient remained stable during her 9-day hospitalization. At her 6-week follow-up she was stable and had resumed a normal routine. The authors suggest the cause of SAH was likely secondary to a suddenly escalation in phentermine [ 60 A].
Nervous system A year-old woman took phentermine , developed altered mental status, and had two generalized seizures [ 77 A ]. She had large bilateral parieto-occipital hemorrhages and was thought to have posterior reversible encephalopathy syndrome with hemorrhagic conversion. Phentermine was withdrawn, and 5 months later an MRI scan showed resolution of the diffuse edema and hemorrhage.
Psychiatric In a study using the Modified Prescription Event Monitoring system, the risks of major and minor depressive episodes in 10 new users of rimonabant were the same overall in the 6 months before and the 6 months after starting treatment [ 81 C ]. The risk of a primary outcome event non-fatal myocardial infarction, non-fatal stroke, resuscitation after cardiac arrest, or cardiovascular death was The rates of non-fatal myocardial infarction and non-fatal stroke were 4.
The rates of cardiovascular death and death from any cause were not increased. Endocrine A year-old woman took sibutramine and developed amenorrhea and galactorrhea with hyperprolactinemia [ 84 A ]. Sibutramine was withdrawn, and her serum prolactin concentration returned to normal within 15 days; the amenorrhea and galactorrhea resolved. Nicolas Rasmussen 1 , in International Review of Neurobiology , Some are mainly consumed on prescription for medically authorized purposes; others, both legally and illegally manufactured, mainly for recreational purposes; and others still in the broad grey zone between, encompassing both nonmedical use of prescribed drugs and unprescribed self-medication.
Many of the other psychostimulants widely used today are derivatives of amphetamine, developed in an effort to maximise one of the founder drug's other three types of action.